Sagimet Biosciences Inc. Series A Common Stock (SGMT) — Cash Flow-to-Debt Ratio
Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a Cash Flow-to-Debt Ratio of -1.47x as of June 2026, meaning its operating cash flow of $-10.70 Million could theoretically repay -1% of its total liabilities ($7.28 Million) in one year. See SGMT financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sagimet Biosciences Inc. Series A Common Stock Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Sagimet Biosciences Inc. Series A Common Stock across 7 annual periods. For the full cash flow conversion analysis, see Sagimet Biosciences Inc. Series A Common cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Sagimet Biosciences Inc. Series A Common Stock (2019–2025)
Year-by-year debt coverage analysis for Sagimet Biosciences Inc. Series A Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -8.95x | $-45.65 Million | $5.10 Million | ▲ +6.1% |
| 2024 | -9.53x | $-42.44 Million | $4.45 Million | ▼ -126.7% |
| 2023 | -4.20x | $-23.77 Million | $5.65 Million | ▼ -3675.7% |
| 2022 | -0.11x | $-24.49 Million | $219.98 Million | ▼ -11.4% |
| 2021 | -0.10x | $-21.71 Million | $217.29 Million | ▼ -96.5% |
| 2020 | -0.05x | $-10.42 Million | $204.87 Million | ▲ +34.2% |
| 2019 | -0.08x | $-10.55 Million | $136.47 Million | — |